Arizona State Retirement System Has $232,000 Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Arizona State Retirement System reduced its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 6.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,121 shares of the biopharmaceutical company’s stock after selling 1,869 shares during the period. Arizona State Retirement System’s holdings in Ocular Therapeutix were worth $232,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in OCUL. Aigen Investment Management LP bought a new stake in Ocular Therapeutix in the 4th quarter valued at about $159,000. Victory Capital Management Inc. grew its stake in Ocular Therapeutix by 300.4% in the fourth quarter. Victory Capital Management Inc. now owns 68,871 shares of the biopharmaceutical company’s stock valued at $588,000 after acquiring an additional 51,671 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Ocular Therapeutix by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after acquiring an additional 21,025 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in shares of Ocular Therapeutix during the fourth quarter worth approximately $897,000. Finally, New York State Common Retirement Fund grew its position in Ocular Therapeutix by 18.4% in the 4th quarter. New York State Common Retirement Fund now owns 98,097 shares of the biopharmaceutical company’s stock valued at $838,000 after purchasing an additional 15,239 shares during the period. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Donald Notman sold 11,119 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock worth $283,772 in the last quarter. 3.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on OCUL. Needham & Company LLC started coverage on shares of Ocular Therapeutix in a report on Tuesday, March 11th. They set a “buy” rating and a $15.00 price objective on the stock. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.29.

Ocular Therapeutix Stock Down 2.0 %

Ocular Therapeutix stock opened at $7.72 on Friday. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The firm’s 50-day simple moving average is $7.69 and its 200 day simple moving average is $8.82. The stock has a market cap of $1.23 billion, a PE ratio of -5.85 and a beta of 1.34.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.